Original Article

Relative Efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
  • Hwan Lee
Mol Imaging Radionucl Ther 2022; 31: 1-6 DOI: 10.4274/mirt.galenos.2021.63308 PMID:35114745
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry
  • Levent Kabasakal
  • Türkay Toklu
  • Nami Yeyin
  • Emre Demirci
  • Mohammad Abuqbeitah
  • Meltem Ocak
  • Aslan Aygün
  • Emre Karayel
  • Hüseyin Pehlivanoglu
  • Nalan Alan Selçuk
Mol Imaging Radionucl Ther 2017; 26: 62-68 DOI: 10.4274/mirt.08760 PMID:28613198

Interesting Image

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
  • Majid Assadi
  • Seyed Javad Rekabpour
  • Abdullatif Amini
  • Habibollah Dadgar
  • Reza Nemati
  • Ali Gholamrezanezhad
  • Iraj Nabipour
  • Esmail Jafari
  • Hojjat Ahmadzadehfar
Mol Imaging Radionucl Ther 2021; 30: 107-109 DOI: 10.4274/mirt.galenos.2020.69783 PMID:34082512
Almost Complete Response with a Single Administration 225Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary
  • Nalan Alan Selçuk
  • Emre Demirci
  • Meltem Ocak
  • Türkay Toklu
  • Selçuk Ergen
  • Levent Kabasakal
Mol Imaging Radionucl Ther 2022; 31: 139-141 DOI: 10.4274/mirt.galenos.2022.64497 PMID:35771003